The estimated Net Worth of Carol D. Karp is at least $1.19 Milion dollars as of 4 October 2023. Ms. Karp owns over 5,000 units of Prothena plc stock worth over $104,650 and over the last 8 years she sold PRTA stock worth over $0. In addition, she makes $1,083,580 as Chief Regulatory Officer at Prothena plc.
Carol has made over 8 trades of the Prothena plc stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 5,000 units of PRTA stock worth $60,750 on 4 October 2023.
The largest trade she's ever made was exercising 20,000 units of Prothena plc stock on 7 June 2023 worth over $263,800. On average, Carol trades about 3,889 units every 42 days since 2016. As of 4 October 2023 she still owns at least 5,000 units of Prothena plc stock.
You can see the complete history of Ms. Karp stock trades at the bottom of the page.
Carol D. Karp serves as Chief Regulatory Officer of the Company. Prior to joining Prothena, she was an independent regulatory consultant to biotechnology and pharmaceutical companies. From 2013 to 2014, Ms. Karp was Senior Vice President, Regulatory Affairs and Compliance at Esperion Therapeutics, Inc. (a biotechnology company), and from 2010 to 2013, she was Vice President, Head of Global Regulatory Affairs, Pharmacovigilance & Risk Management at Janssen Alzheimer Immunotherapy, a Johnson & Johnson Company (a biopharmaceutical company). Previously, Ms. Karp held senior regulatory positions at Janssen Alzheimer Immunotherapy, CV Therapeutics, Inc., PowderJect Technologies, VIVUS, Inc., Cygnus, Inc. and Janssen Pharmaceutica. She earned her BA in Biology from the University of Rochester, where she is a member of the Board of Trustees.
As the Chief Regulatory Officer of Prothena plc, the total compensation of Carol Karp at Prothena plc is $1,083,580. There are 4 executives at Prothena plc getting paid more, with Wagner Zago having the highest compensation of $3,341,640.
Carol Karp is 67, she's been the Chief Regulatory Officer of Prothena plc since 2016. There are 4 older and 20 younger executives at Prothena plc. The oldest executive at Prothena Corporation plc is Christopher Henney, 78, who is the Independent Director.
Carol's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Over the last 12 years, insiders at Prothena plc have traded over $79,429,035 worth of Prothena plc stock and bought 2,987,732 units worth $75,619,043 . The most active insiders traders include Capital, Llc Eco R1, Co Plc Elan Corp Plc Elan S... a Helen Susan Kim. On average, Prothena plc executives and independent directors trade stock every 21 days with the average trade being worth of $946,769. The most recent stock trade was executed by Karin L Walker on 24 January 2024, trading 5,000 units of PRTA stock currently worth $67,650.
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
Prothena plc executives and other stock owners filed with the SEC include: